Detalles de la búsqueda
1.
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.
Ann Oncol
; 31(8): 1030-1039, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32339648
2.
Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.
Ann Oncol
; 29(10): 2098-2104, 2018 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30412222
3.
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.
Ann Oncol
; 28(11): 2754-2760, 2017 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28950297
4.
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.
Ann Oncol
; 28(6): 1339-1345, 2017 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28327953
5.
Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors.
Br J Dermatol
; 176(6): 1649-1652, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27943234
6.
Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy.
Ann Oncol
; 27(3): 519-25, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26759276
7.
Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma.
Ann Oncol
; 27(7): 1304-11, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27059553
8.
Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4).
Ann Oncol
; 27(3): 441-8, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26681676
9.
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.
Br J Cancer
; 112(7): 1190-8, 2015 Mar 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-25695485
10.
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
Br J Cancer
; 110(12): 2821-8, 2014 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-24823696
11.
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.
Br J Cancer
; 110(5): 1125-32, 2014 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-24434434
12.
Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.
Ann Oncol
; 25(3): 663-668, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24458473
13.
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial.
ESMO Open
; 9(5): 102994, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38642472
14.
Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial.
Br J Cancer
; 108(8): 1571-8, 2013 Apr 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-23579211
15.
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma.
Br J Cancer
; 108(12): 2470-7, 2013 Jun 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-23695024
16.
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.
Ann Oncol
; 29(11): 2269, 2018 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29390043
17.
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma.
ESMO Open
; 8(3): 101210, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37104931
18.
Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101.
ESMO Open
; 8(6): 102034, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37866029
19.
Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma.
Br J Cancer
; 106(4): 646-50, 2012 Feb 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-22240794
20.
Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α.
Br J Cancer
; 106(10): 1587-90, 2012 May 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-22568998